PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.
Finasteride, dutasteride, saw palmetto, caffeine, spironolactone, acetyltetrapeptides, tea tree oil, hydrocortisone, zinc pyrithione, latanoprost, melatonin, marine protein supplements, PRP, microneedling, and valproate are discussed as treatments for hair loss. DHT reduction and inflammation control are key strategies.
The conversation is about hair loss treatments, specifically discussing the effectiveness of Red Ginseng Extract in promoting hair growth. Other treatments mentioned include Minoxidil, finasteride, and RU58841.